ResearcherUniversity at Buffalo, State University of New YorkActive in the last 2 years
Xin Miao
Matched on ORCID iD 0000-0002-0245-7579; OpenAlex author ID A5101778308. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2016: 2 papers · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 2 papers
Papers 5
- Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Signal Transduction Pathways Related to Tu… Co-author DOI 10.1016/j.xphs.2023.10.030↗
- Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, DNA Damage Response, and Apoptosis Pathw… Co-author DOI 10.1016/j.xphs.2023.10.036↗
- LncRNA SNHG16 contributes to tumor progression via the miR-302b-3p/SLC2A4 axis in pancreatic adenocarcinoma. First author DOI 10.1186/s12935-020-01715-9↗
- Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells. Co-author DOI 10.1007/s00280-015-2907-4↗
- Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells. Co-author DOI 10.3389/fphar.2016.00421↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Robert M. Straubinger · 4 shared papers, 2016–2024 · strength 0.60
- Paper Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Si… DOI 10.1016/j.xphs.2023.10.030↗
- Paper Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, … DOI 10.1016/j.xphs.2023.10.036↗
- Paper Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabecte… DOI 10.1007/s00280-015-2907-4↗
- William J. Jusko · 4 shared papers, 2016–2024 · strength 0.60
- Paper Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Si… DOI 10.1016/j.xphs.2023.10.030↗
- Paper Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, … DOI 10.1016/j.xphs.2023.10.036↗
- Paper Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabecte… DOI 10.1007/s00280-015-2907-4↗
- Jun Qu · 2 shared papers, 2024 · strength 0.43
- Paper Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part I: Effects on Si… DOI 10.1016/j.xphs.2023.10.030↗
- Paper Systems Pharmacodynamic Model of Combined Gemcitabine and Trabectedin in Pancreatic Cancer Cells. Part II: Cell Cycle, … DOI 10.1016/j.xphs.2023.10.036↗
- Xue Wang · 1 shared paper, 2024 · strength 0.22
- Hao Xu · 1 shared paper, 2021 · strength 0.16
- Wence Zhou · 1 shared paper, 2021 · strength 0.16
- Bo Zhang · 1 shared paper, 2021 · strength 0.16
- Xin Li · 1 shared paper, 2021 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.